Papillary thyroid carcinoma is a risk factor for severe osteoporosis

Area of Science:

• Endocrinology
• Oncology
• Bone Metabolism

Background:

• Thyroid-stimulating hormone (TSH)-suppressive therapy is standard for high-risk papillary thyroid carcinoma (PTC) patients post-surgery.
• TSH-suppressive therapy is a known risk factor for osteoporosis and fractures.
• The independent risk of PTC itself for osteoporosis remains unclear.

Purpose of the Study:

• To determine if papillary thyroid carcinoma (PTC) is an independent risk factor for osteoporosis.
• To compare osteoporosis prevalence in PTC patients versus healthy individuals.

Main Methods:

• Evaluated serum/urinary biochemical markers, bone mineral density (BMD), and vertebral fractures (VFs) in 35 PTC patients and 35 controls.
• Compared parameters between PTC and control groups.
• Performed multivariate logistic regression analyses adjusting for age, BMI, eGFR, and HbA1c.

Main Results:

• PTC patients had higher BMI, HbA1c, and lower eGFR and intact PTH than controls.
• No significant differences in overall osteoporosis or VF prevalence were found.
• Severe osteoporosis prevalence was significantly higher in PTC patients (34.3%) vs. controls (11.4%).
• PTC was independently associated with severe osteoporosis (OR, 4.20; 95% CI, 1.05-16.8).

Conclusions:

• Papillary thyroid carcinoma (PTC) is identified as an independent risk factor for severe osteoporosis.
• This association persists regardless of BMI, renal function, or glucose levels.
• Findings highlight the need for monitoring bone health in PTC patients.